2003, FDA Approval, Pharmaceuticals and Small Molecule

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

FDA Approval

Pharmaceuticals

Small Molecule

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. Food and Drug Administration (FDA) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp. The FDA approval of Klisyri is a significant milestone for Athenex.

FDA Approval

FDA Approval FDA Treatment Small Molecule

Zavegepant

New Drug Approvals

JULY 10, 2023

If FDA approved, it will join other previously-approved “-gepant” drugs [ rimegepant ] and [ ubrogepant ] as an additional treatment alternative for patients with migraine, particularly those for whom traditional triptan therapy has proven ineffective. The clinical trial is expected to complete in September 2020.

Clinical Trials

Clinical Trials Treatment FDA Trials

Drug Discovery Digest

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

Zavegepant

Stay Connected